Erasca(US:ERAS)2025-11-12 21:09Financial Performance - Erasca reported cash, cash equivalents, and marketable securities of $362.4 million as of September 30, 2025, down from $440.5 million as of December 31, 2024, with expectations to fund operations into H2 2028[5] - Net loss for Q3 2025 was $30.6 million, or $(0.11) per share, compared to a net loss of $31.2 million, or $(0.11) per share, for Q3 2024[8] - Total operating expenses for Q3 2025 were $34.5 million, a decrease from $37.2 million in Q3 2024[15] - The accumulated deficit increased to $863.1 million as of September 30, 2025, compared to $767.7 million as of December 31, 2024[14] - Total stockholders' equity decreased to $347.9 million as of September 30, 2025, down from $423.5 million as of December 31, 2024[14] Research and Development - Research and development (R&D) expenses decreased to $22.5 million for Q3 2025, compared to $27.6 million for Q3 2024, primarily due to reduced clinical trial and preclinical study costs[6] - Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 is expected in 2026, indicating progress in clinical development[2] Administrative Expenses - General and administrative (G&A) expenses increased to $10.1 million for Q3 2025, up from $9.6 million for Q3 2024, driven by higher legal fees and personnel costs[7] Intellectual Property - The U.S. Patent and Trademark Office issued a patent for ERAS-0015, providing composition of matter protection until September 2043[3] Leadership Changes - Erasca promoted Robert Shoemaker, Ph.D., to chief scientific officer, strengthening its scientific leadership[4]